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Abstract
Background: Viral load is still the marker of choice for monitoring adherence to combined antiretroviral therapy
(cART) and confirming the success of HIV treatment. Unfortunately it is difficult to access in many resource-poor
settings. We aimed to measure the performance of caregiver reporting adherence for detecting virological failure in
routine practice during the first 2 years after cART initiation in infants.
Methods: PEDIACAM is an ongoing prospective cohort study including HIV1-infected infants diagnosed before
7 months of age between November 2007 and October 2011 in Cameroon. Adherence was assessed using a
questionnaire administered every 3 months from cART initiation; the HIV-RNA viral load was determined at the
same visits. Virological failure was defined as having a viral load ≥ 1000 cp/mL at 3 and 12 months after cART
initiation or having a viral load ≥ 400 cp/mL at 24 months after cART initiation. The performance of each current
missed and cumulative missed dose defined according to adherence as reported by caregiver was assessed using
the viral load as the gold standard.
Results: cART was initiated at a median age of 4 months (IQR: 3–6) in the 167 infants included. The cumulative
missed dose showed the best overall performance for detecting virological failure after 12 months of cART (AUC
test, p = 0.005, LR + =4.4 and LR− = 0.4). Whatever the adherence reporting criterion, the negative predictive value
was high (NPV ≥ 75 %) 12 and 24 months after cART initiation, whereas the positive predictive value was low
(PPV≤ 50 %).
Conclusions: The adherence questionnaire administered by the health care provider to the infants’ caregivers is
not reliable for detecting virological failure in routine practice: its positive predictive value is low. However, the
cumulative missed dose measurement may be a reliable predictor of virological success, particularly after
12 months of cART, given its high negative predictive value.
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Background
Mortality and morbidity due to HIV/AIDS in both adults
and children has been dramatically reduced by combined
antiretroviral therapy (cART) [1–3]. The CHER study
showed that early initiation of cART in infants, before
3 months of age, reduced mortality by around 75 % [1].
Thus, in 2008 the WHO recommended that all HIV-
infected infants diagnosed before age 2 years be immedi-
ately treated, regardless of clinical, immune or virological
status; in 2013, the WHO further recommended a rapid
scale-up of systematic cART to any HIV-infected child
under 5 years of age [1–4].
Satisfactory virological and clinical responses require
adherence to cART; adherence also limits the emergence
of antiretroviral drug resistance, particularly important in
resource-limited settings with restricted cART regimen
options [5–11]. Viral load measurement is the best marker
of response to cART which is strongly reflective of
adherence to cART in patients whose strains are suscep-
tible to antiretroviral treatment they are receiving. But it is
difficult to access for routine use in many resource-limited
settings. There are other indicators some of which have
been used in biomedical research: direct measures,
including assaying plasma for drugs or drug metabolites;
and indirect evaluations including self-reports, electronic
drug monitoring, pill counts and pharmacy refill records
[12–18]. Electronic drug monitoring appears to be the
most sensitive indirect method for detecting missed
doses of medication, but is difficult to implement in a
resource-limited setting [13].
Pediatric cART is increasingly widely used in low-
income countries and therefore there is a corresponding
need for reliable methods, easier to access than viral load
determinations, for assessing infant adherence to cART in
routine practice. We are unaware of any previous study in
Sub-Saharan Africa using indirect evaluations specifically
to evaluate the adherence to cART among infants.
The main objective of this study was to assess the
performance of caregiver adherence reporting question-
naires for detecting virological failure in routine practice
during the first 2 years of cART in infants in Cameroon.
Methods
The ANRS-12140 Pediacam Study
PEDIACAM is a prospective cohort study of HIV-infected
infants included between November 2007 and October
2011 in three referral hospitals in Cameroon: the Centre
Mère et Enfant de la Fondation Chantal Biya (CME/FCB)
and Centre Hospitalier d’Essos (CHE) both in Yaounde
and Hôpital Laquintinie de Douala (HLD) in Douala. The
inclusions in PEDIACAM were organized in two phases
and are described elsewhere [18]. In brief, during the first
phase, infants born to HIV-infected mothers and those
born to HIV-uninfected mothers were matched according
to gender and site of recruitment during the first week of
life and followed until the fourteenth week. During the
follow-up period, all infants received routine vaccines
according to the Expanded Program of Immunization,
planned at 6, 10 and 14 weeks. HIV-exposed infants
underwent HIV molecular diagnostic tests (HIV-DNA
PCR or HIV-RNA PCR) at 6 weeks of age and the results
were available at week 10. HIV-positive infants were
confirmed by testing a second sample collected at age
10 weeks. Breastfed infants with previously negative
HIV tests were retested 6 weeks after weaning. All
HIV-infected infants and subsamples of uninfected
HIV-exposed infants and HIV-negative unexposed
infants were eligible for the second phase of follow-
up planned to continue to age 2 years. Inclusion into
phase 2 was also offered directly to HIV-infected infants
not followed from the first week of life but diagnosed
before the age of 7 months.
Overall, 210 HIV-infected infants were included in the
second phase: cART was proposed systematically to
these children as soon as the HIV status was confirmed.
The initial cART regimen depended on PMTCT
(Prevention of Mother-to-Child Transmission) history
and followed the Cameroonian guidelines at the time
of the study which recommended zidovudine (or aba-
cavir or stavudine if anemic), lamivudine and lopina-
vir/r if there was any use of nevirapine for PMTCT
(or nevirapine otherwise). The caregivers were asked to
administer the drugs to the infants twice daily (every
12 h). A standardized questionnaire was administered
every 3 months after initiation of cART by a health care
provider (physician, nurse, psychosocial worker or
pharmacist) to assess infant adherence to cART during
the period and to identify and help families with any
difficulties. In total, eight questionnaires were planned
from month 3 (M3) to month 24 (M24) of follow-up. The
HIV viral load was measured at the same follow-up time
points using RT PCR (Biocentric, Bandol, France).
Caregiver adherence questionnaire
The adherence questionnaire was similar to the question-
naire used in the PENTA trial, with some adaptations
[16]. It included questions about: the relationship between
the caregiver and the child; difficulties experienced during
drug administration; the most difficult dose to remember;
how administration of cART interfered with everyday life;
reasons for the difficulties identified; and the caregiver’s
recall of missed doses in the past 3 and 14 days.
Study population
Among the 210 HIV-infected infants included in phase 2
of the PEDIACAM study, 13 died before treatment
started and five refused cART. For the 192 infants who
initiated cART, 25 died during the first three months of
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treatment. Thus, 167 HIV-infected infants treated for at
least three months were included in this analysis (Fig. 1).
Infants without virological data at a particular time point
(because of death or missing values) were not included
in the analysis at that particular time point. There were:
33 (19.8 %) such children at M3, 9 (5.4 %) at M12 and 6
(3.6 %) at M24.
Variables and statistical analysis
The quarterly monitoring values used were the nearest
measurement within a ±1.5 month interval of each of
the following times after cART initiation: M3, M6, M9,
M12, M15, M18, M21 and M24.
The main outcome was virological failure at M3, M12
and M24, defined as viral load higher than 1000 copies/
mL (at M3 or M12) or higher than 400 copies/mL (at
M24). We chose a higher threshold for M3 and M12
because a previous African study of HIV-infected infants
under 12 months of age reported very high viral loads at
baseline and that treatment duration contributed to
lower viral loads at M24 [19]. HIV resistance genotyping
by sequence amplification and interpretation according to
the French ANRS interpretation algorithms was carried
out for selected cases of virological failure associated with
reporting suggesting adequate adherence.
The outcome measures also included non-adherence
at the various time points recorded as: “current missed
doses” (criterion A) defined as the number of cART
doses not administered to an infant at a particular time
point (M3, M12 or M24) and “cumulative missed doses”
(criterion B) which was the sum of cART doses reported
as not administered every three months during the
corresponding interval M3 to M12 or M3 to M24. We
also used mixed criteria (A or B, A and B). When a quar-
terly visit was lacking, all the cART doses for this visit
were considered to be missing. When a quarterly visit was
performed but the adherence questionnaire not com-
pleted, we considered the previous number of missed
doses for that particular visit.
Many different thresholds (5, 10, 15 and 20 %) for
current missed doses have been used in previous studies
in the literature to define non-adherent HIV-infected
patients [13, 14, 16, 19–21]. We compared many of these
thresholds, using receiver operating characteristic (ROC)
curves, maximizing the sensitivity, to determine cutoff
points for missed dose values that are optimal for
detecting virological failure at the various time points
HIV-infected infants (N=210)
Treated (N=192)Not treated (N=18)
-cART refusal: 5
-relocation: 1
-early death before cART: 12 
Died before M3 (N=25)
HIV infected infants not followed from birth 
and diagnosed before 7 months of age (N=141)
HIV infected infants followed 
from birth (N=69)
Still alive (N=154)
- M24 visit performed (n=144)
- M24 visit not performed (n=10) 
Dead (N=13)
- Before M12 (n=9)
- Between M12 and M24 (n=4)
Still alive at M3
Included in the study 
(N=167)
Evaluation at M24 
Fig. 1 Cohort description (ANRS-PEDIACAM Study, 2008-2013, Cameroon). Legend: N, number; cART, combined antiretroviral therapy; Mx, delay
from ART initiation to the current visit, e.g. «M3» means «3 months after cART initiation»
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(viral load ≥1000 copies/mL at M3 and M12, or ≥400 cop-
ies/mL at M24). Infants with values above this cut-off
were defined as non-adherent. We performed area under
the curve (AUC) tests for criteria A and B for M3, M12
and M24. We estimated the sensitivity (proportion identi-
fied as non-adherent among children with virological fail-
ure) and specificity (proportion identified as adherent
among those with virological success) of the approach.
We also estimated positive predictive value (PPV; prob-
ability of virological failure among children whose care-
giver reported non adherence) and negative predictive
value (NPV; probability of virological success among chil-
dren whose caregiver reported adherence). We then esti-
mated positive and negative likelihood ratios (LR): the
ratio of probability to be “non-adherent” (LR+) or to be
“adherent” (LR−) for a child with virological failure versus
virological success.
We studied associations between missed dose A or B
criteria and various other items in the adherence ques-
tionnaire: problems with giving medication (difficulties
during drug administration, the most difficult dose to re-
member, how administration of cART interferes with
everyday life, reasons for the difficulties), type of care-
giver and health care provider, the time point of the visit.
Univariate analysis was first performed, using Chi square
or Fisher’s exact test, as appropriate. Adjusted odds ratios
(aOR) were estimated in multivariate logistic regression
models, with reported missed dose as the dependent vari-
able. For all analyses, p-values less than 0.05 (two-sided)
were considered statistically significant. All the statistical
analyses were performed using STATA 12.0 (StataCorp,
College Station, TX).
Ethical consideration
The ANRS-PEDIACAM study was granted ethical ap-
proval in Cameroon by the National Ethics Committee
and in France by the Biomedical Research Committee of
the Pasteur Institute of Paris. The Cameroon Ministry of
Public Health gave administrative authorization to start
the study. Caregivers signed written informed consent
for participating in the study.
Results
Study population
Among the 167 HIV-infected children included (Fig. 1)
in this analysis, 45.5 % were boys. Half of the infants
were living with both of the parents, 38 % with their
mothers only and 12 % with other caregivers; 6.6 % were
motherless orphans (Table 1). cART was initiated at me-
dian age of 4 months (IQR: 3–9), when the median viral
load (VL) was 6.5 log10 copies/mL (IQR: 6.0–6.9) and
median CD4 percentage 22 % (IQR: 15–31 %). Respect-
ively 34 and 64 % of infants started cART with
nevirapine-based and lopinavir-based regimens. Three
quarters of the infants were enrolled in Yaounde. Two
years after cART initiation, 92.2 % (154/167) of infants
were alive, and 144 attended the M24 visit. Thirteen in-
fants died, including nine before M12, and four between
M12 and M24 (Table 2).
Adherence reporting by caregivers
Adherence questionnaires were administered by physi-
cians (34.8 %), pharmacists (31.5 %), psychosocial
workers (19.8 %) and nurses (13.9 %), and the respond-
ent was mostly the mother (in 79.0 % of cases at M3,
73.1 % at M12 and 71.6 % at M24). According to respon-
dents, cART medication was usually administered by the
mother (84.3 % at M3, 81.1 % at M12 and 77.9 % at
M24) although other caregivers may also have been in-
volved in cART administration (63.8, 70.2 and 73.8 %,
respectively).
For current missed doses (criterion A), the cutoff point
which provided the best compromise between sensitivity
and specificity, according ROC curves, was ≥1 missed
dose at all visits (Table 3). For cumulative missed doses
(criterion B), the best cutoff points were ≥2 missed doses
at M12 and ≥8 missed doses at M24. With these cutoff
points, the proportions of non-adherent children accord-
ing to reported current missed dose were 27.4 % (40/
146) at M3, 11.1 % (14/126) at M12 and 13.9 % (11/79)
at M24. The proportions, based on the cutoff values for
cumulative missed doses, were 23.8 % (30/126) at M12
and 62.0 % (49/79) at M24.
The area under the curve (AUC) was not significantly
different to 0.5 for any missed dose criterion, except for
cumulative missed doses at M12 (p = 0.005 for VL ≥
1000 cp/mL) (Table 3 and Fig. 2).
Virological failure
The proportions of infants with virological failure (de-
fined as >1000 copies/mL) 3 and 12 months after cART
initiation were respectively: 47.8 % (61/146) and 23.8 %.
Twenty-four months after cART initiation, the propor-
tion of virological failure (defined as >400 copies/mL)
was 27.9 % (22/79) (Table 2).
Performance of caregiver questionnaire about adherence
The best sensitivity was observed with the cumulative
missed doses criterion as reported at M12 (63.3 %) and
M24 (72.7 %). But its specificity decreased with time (to
67.7 % and 42.1 %, respectively). For all criteria used, the
PPV was low (≤50 %) and NPV was high (≥75 %) at both
M12 and M24. Cumulative missed doses at M12 gave
the best likelihood ratios (LR + =2.0 and LR− = 0.5)
(Table 3). The mixed criterion for non-adherence did
not perform better at detecting virological failure.
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Similar results were obtained when the analysis was
restricted to the more than 70 % of the children accom-
panied by their mothers (Table 3).
According to both current and cumulative missed dose
criteria, 11 children at M12 and 3 at M24 were classified
as adherent although viral load testing indicated viro-
logical failure: they were tested for genotypic antiretroviral
resistance and resistance to the currently used cART was
detected in seven cases. All viruses were non-B subtypes.
The most prevalent mutations in the Protease gene were
I13V, K20I, M36I, H69K and L89M, and the mutations in
the Reverse Transcriptase gene were T215S, M184V and
Y181C.
Thirteen children identified as virological successes
at M12 (VL < 1000 cp/mL) and 20 children as
virological successes at M24 (VL < 400 cp/mL) were clas-
sified as non-adherent according to cumulative missed
dose criteria but adherent according to current missed
dose criteria.
Factors associated with missed dose reporting
Missed dose reporting was not significantly associated
with health care provider, visit time point or caregiver.
Table 1 Description of baseline characteristics of HIV-infected
infants treated by cART for at least 3 months (ANRS-PEDIACAM
Study, 2008-2013, Cameroon)
N = 167
Variables (n, % of missing data) N % (n) or
median (IQR)
Male sex 167 45.5 (76)
Infant group at inclusion 167
Followed since birth 37.7 (63)
Not followed since birth but diagnosed before
age 7 months
62.3 (130)
Recruitment sites 167
CME/FCB 47.3 (79)
HLD 23.4 (39)
CHE 29.3 (49)
History of breastfeeding 110 51.8 (57)
Vital status of parents at cART initiation 167
Mother dead 6.6 (11)
Father dead 3.6 (6)
Vital status of the father unknown
(or data missing)
6.6 (11)
Infants living with: 167
Both parents 50.3 (84)
Mother only 37.7 (63)
Other caregivers 12.0 (20)
Presence of functional fridge at home 115 43.5 (50)
Difficulty with remembering to give cART
medication
M3 138 33.3 (46)
M12 123 24.4 (30)
M24 81 29.6 (24)
Clinical status at cART initiation 167
WAZ (median, IQR) −0.2 (−0.4; −0.1)
History of hospitalization 41.3 (69)
CD4 count (%) at cART initiation (median, IQR) 161 23 (15 ; 32)
Viral load at cART initiation (log10 cp/mL)
(median, IQR)
166 6.5 (6.0 ; 6.9)
Age at cART initiation 167
< 6 months 80.8 (135)
6–12 months 16.8 (28)
> 12 months 2.4 (4)
In months (median, IQR) 4.0 (3.0–9.0)
Type of first cART 167
Protease inhibitor-based regimen 63.9 (110)
Nevirapine-based regimen 34.1 (57)
N total number, n number of children in the group, CME/FCB Centre Mère et
Enfant/Fondation Chantal Biya, Yaounde, HLD Hôpital Laquintinie, Douala, CHE
Centre Hospitalier d’Essos, Yaounde, Mx delay from cART initiation to the
current visit, e.g. «M3» means «3 months after cART initiation», cART
combination antiretroviral therapy, % percentage, n number of patients in the
cell, WAZ Weight for Age Z score based on WHO reference tables, IQR
interquartile range, CD4 lymphocytes that have CD4 marker
Table 2 Follow-up of infants treated by cART for at least
3 months (ANRS-PEDIACAM Study, 2008–2013, Cameroon)
N = 167
M3 visit M12 visit M24 visit
% (n) % (n) % (n)
Dead 0.0 (0) 5.3 (9)a 2.4 (4)b
Visit not performed 20.4 (34) 23.4 (39) 29.1 (64)
Visit performed 79.6 (133) 71.3 (119) 48.5 (81)
Viral load (cp/mL)
< 400 35.3 (59) 52.7 (88) 34.1 (57)
[400-1000] 15.6 (26) 4.8 (8) 3.6 (6)
≥ 1000 36.5 (61) 18.0 (30) 9.6 (16)
not measured 12.6 (18) 24.5 (41) 59.3 (88)
Accompanied by:
Mother 79.0 (105) 73.1 (87) 71.6 (58)
Grandmother 8.3 (11) 8.4 (10) 8.6 (7)
Aunt 5.9 (8) 5.9 (7) 5.0 (4)
Other 6.8 (9) 12.6 (15) 14.8 (12)
Questionnaire completed N = 151 N = 126 N = 126
Questionnaire completed
and viral load measured
N = 144 N = 125 N = 67
cART combined antiretroviral therapy, N total number, Mx delay from ART
initiation to the current visit, e.g. «M3» means «3 months after cART initiation», %
percentage; n number of patients in the cell
a<12 months
b12 to 24 months
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Discussion
This study is the first to evaluate the value of a face-to-
face adherence reporting questionnaire administered to
caregivers for detecting virological failure 3, 12 and
24 months after initiation of cART for HIV-infected
infants less than 6 months of age in an African country.
As described elsewhere [13, 14, 16, 17, 19–21], we used
criteria based on the number of missed doses at the time
of evaluation (current) or between initiation of cART and
the time of evaluation (cumulative).
The measure based on current missed doses had
only low sensitivity; cumulative missed doses reported
at M12 performed better for detecting virological
failure (significant AUC test with p = 0.010, LR + =2.0
Table 3 Performance of reported adherence for detecting virological failure in HIV-infected infants treated early by cART for at least
3 months (ANRS-PEDIACAM Study, 2008–2013, Cameroon)
3a - All children AUC Sensitivity Specificity PPV NPV LR+ LR−
N % n % p % (n/N) % (n/N) % (n/N) % (n/N)
At M3 146
VL≥ 1000 cp /mL 41.8 (61)
≥ 1 current missed (A) 27. 4 (40) 49.4 0.870 26.2 (16/61) 71.8 (61/85) 40.0 (16/40) 57.5 (61/106) 1.0 1.0
At M12 126
VL≥ 1000 cp /mL 23.8 (30)
≥ 1 current missed (A) 11.1 (14) 53.8 0.260 16.7 (5/30) 90.6 (87/96) 35.7 (5/14) 77.7 (87/112) 1.8 0.9
≥ 2 cumulative missed (B) 23.8 (30) 64.2 0.005 63.3 (19/30) 67.7 (65/96) 38.0 (19/50) 85.5 (65/76) 2.0 0.5
A or B 63.3 (19/30) 65.6 (63/96) 36.5 (19/52) 85.1 (63/74) 1.8 0.6
A and B 16.7 (5/30) 89.6 (86/96) 41.7 (5/12) 78.1 (89/114) 2.3 1.0
At M24 79
VL > 400 cp /mL 27.8 (22)
≥ 1 current missed (A) 13.9 (11) 56.6 0.100 22.7 (5/22) 89.5 (51/57) 45.5 (5/11) 75.0 (51/68) 2.2 0.9
≥ 8 cumulative missed (B) 62.0 (49) 57.7 0.130 72.7 (16/22) 42.1 (24/57) 32.7 (16/49) 80.0 (24/30) 1.3 0.7
A or B 72.7 (16/22) 40.4 (23/57) 32.0 (16/50) 79.3 (23/29) 1.2 0.7
A and B 22.7 (5/22) 91.2 (52/57) 50.0 (5/10) 75.4 (52/69) 2.6 0.9
3b Children accompanied by mothers AUC Sensitivity Specificity PPV NPV LR+ LR−
N % n % p % (n/N) % (n/N) % (n/N) % (n/N)
At M3 116
VL≥ 1000 cp /mL 41.4 (48)
≥ 1 current missed (A) 25.0 (29) 49.9 0.510 21.7 (12/48) 72.6 (51/68) 41.4 (12/29) 58.6 (51/87) 1.0 1.0
At M12
VL≥ 1000 cp /mL 92 22.8 (21)
≥ 1 current missed (A) 92 13.0 (13) 50.7 0.120 14.3 (3/21) 87.3 (62/71) 25.0 (3/12) 77.5 (62/80) 1.1 1.0
≥2 cumulative missed (B) 67 30.4 (21) 68.1 0.010 64.3 (9/14) 77.4 (43/55) 42.9 (9/21) 89.6 (43/48) 3.0 0.5
A or B 92 76.2 16/21) 57.8 (41/71) 34.8 (16/46) 89.1 (41/46) 1.8 0.4
A and B 92 14.3 (3/21) 95.8 (68/71) 50.0 (3/6) 79.1 (68/86) 3.4 0.9
At M24
VL > 400 cp /mL 53 24.5 (13)
≥ 1 current missed (A) 53 9.4 (5) 51.4 0.410 7.7 (1/13) 90.0 (36/40) 20.0 (1/5) 75.0 (36/48) 0.8 1.0
≥ 8 cumulative missed (B) 4 0 (0) NA NA NA NA NA NA NA NA NA NA NA NA
A or B 53 100 (13/13) 5.0 (2/40) 25.5 13/51 100 (2/2) 1.1 0.0
A and B 4 NA NA NA NA NA NA NA NA NA NA
cART combined antiretroviral therapy, VL viral load, Mx duration covered from cART initiation to current visit, e.g. «M3» means «3 months duration since cART
initiation», N total number, % percentage, n number of patients in the group, IQR interquartile range, current number of missed doses during the previous 3 days,
cumulative total number of accumulated missed doses from M3 to current visit (M12 or M24), N total size, PPV positive predictive value, NPV negative predictive
value, p AUC test, LR+ positive likelihood ratio, LR− negative likelihood ratio, NA not applicable, due to absence of patients with both virological failure
and non-adherence
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and LR− = 0.5). This means that the probability of
classifying a child as “non-adherent” is 2 times higher
if he/she is in virological failure than success. Con-
versely, the probability of being classified as “adherent” is
2 times higher in cases of virological success than failure.
For all criteria considered, the negative predictive
values were mostly higher than 75 % but positive
predictive values were mostly below 50 %. Few relevant
studies report estimates of likelihood ratios and predict-
ive values. Predictive values are more helpful than
specificity and sensitivity for clinical decision-making in
routine practice, but depend on the prevalence of viro-
logical failure in the population studied. Here, preva-
lence of virological failure was 47.8 % at M3, 23.8 % at
M12 and 27.9 % at M24, which explains the high NPV.
A cohort study in Uganda reported that 28.8 % (17/59)
of children had viral loads ≥1000 copies/mL at M12, and
this is consistent with our findings [20].
Some children were classified as non-adherentaccording
to cumulative missed dose, because of poor adherence
at the beginning or part way through cART although
they subsequently improved and obtained virological
success at M12 or M24. This led to false positive
cases, erroneous detection of virological failure and
consequently decreased specificity, LR+ and PPV,
particularly at M24. The single measures of viral load
at M12 and M24 did not allow us to examine short-
term effects of adherence fluctuations on virological
outcomes [14].
Other children were classified as “adherent” although
they showed virological failure at M12 or M24, which
would be considered false negatives, reducing the sensi-
tivity, NPV and LR+ of caregiver adherence reporting as
a test for virological failure. Among the 11 infants pre-
senting with these “divergent” unexpected results, 7
had genotypic evidence of resistance to antiretrovirals
in their regimens. The findings from this study strongly
suggest that in the majority of cases, patients whose care-
givers report high adherence and have virological failure
have resistance mutations. The caregiver desire to
please health care providers, as reported in previous
studies [4, 12, 22–25], account for a minority of dis-
crepant adherence-virological response findings.
Other factors which were not assessed by our study may
be involved, such as concomitant disease, insufficient
doses of ARV at home, drug interactions, individual differ-
ences in drug absorption and metabolism [4].
The sensitivity of the current missed dose measure for
detecting virological failure was low and did not signifi-
cantly vary over time during the first 2 years of cART.
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Fig. 2 ROC curve for various reporting adherence criteria (ANRS-PEDIACAM Study, 2008-2013, Cameroon). Legend: cART, combined
antiretroviral therapy
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Reporting a non-null number of missed doses is likely to
indicate that some of the doses was taken only in part,
rather an exact number completely not consumed [13].
This type of measure was similarly found in a Zambian
study to have low sensitivity after 24 months of cART in
adults with median ART duration of 2 years [25]. Ac-
cording to the current missed dose measure, the propor-
tion of non-adherent children at M12 in our cohort
(10.4 %) was similar to those reported in older children
in South African (13.8 %) and Ugandan (14 %) studies
[14, 22]. The proportion of non-adherence at M24 in a
Ugandan study of children aged 2–10 years (3.3 %) [17]
was smaller than that in our study (13.9 %), possibly be-
cause the administration of medication to older children
is easier.
Our study has some limitations including sample size
to be analyzed at M12 and in particular at M24 being
smaller than the number of children initially eligible for
the study. This may have reduced the statistical power
(sensitivity) for detection of virological failure. Viral
load measurements were not made for some children
because of death, loss to follow-up and caregiver
decision to leave the health facility before blood could
be drawn at the lab for plasma HIV-1 RNA tests. The
ANRS 12140-PEDIACAM initially planned to follow
HIV-infected infants until 2 years of age; however,
many of the children who reached age 2 years (65 of
144) had not completed 2 years of cART and their
viral loads were not subsequently measured. There
was no association found between absence of viral load
measurement at M12 or M24 and baseline characteristics.
Conclusions
In conclusion, the adherence questionnaire administered
by the health care provider to the infant’s caregiver is
not a useful tool for detecting virological failure. As
described for older children, its performance is poor,
and its positive predictive value is too low for use in
routine practice. Therefore, viral load measurement re-
mains the best approach in routine practice to managing
children under antiretrovirals and to avoid the emergence
of resistance. We nevertheless report that the adherence
questionnaire has a relatively high negative predictive
value; adherence questionnaires and caregiver reporting
may be useful in similar resource-limited settings, not to
detect virological failure, but to identify virological success
or resistance to antiretrovirals (in case of clinical or im-
munological discordance). Indeed, two or fewer missed
doses reported in all trimestral questionnaires during the
12 months following the initiation of treatment is reassur-
ing for the continuation of the treatment unchanged if the
clinical and immunological status is satisfactory. Discord-
ance suggests that it may be valuable to interview the
family carefully, or propose home visits to identify any
difficulties experienced with administration of medica-
tions, or to conduct genotyping tests.
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